Patient eligibility
The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with palovarotene under the National Health Act 1953, section 85 for patients with FOP.
Patients must be eligible for the PBS and meet the relevant restriction criteria.
The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing palovarotene.
Treatment specifics
To be eligible for PBS-subsidised treatment with palovarotene, patients must be treated by, or in consultation with, a specialist medical practitioner experienced in the diagnosis and management of FOP.
Authority applications
Applying for chronic treatment
Please note: You don’t need to complete this application in writing when you request PBS authority online.
Applications for authority approval to prescribe PBS-subsidised palovarotene for chronic treatment of FOP can be made:
- using the Online PBS Authorities system
- in writing and use HPOS Form upload
- in writing and mail to PBS Complex Drugs Programs.
All written applications must include:
- details of the proposed prescription or prescriptions
- the completed fibrodysplasia ossificans progressiva - palovarotene - chronic treatment authority application form
- relevant attachments.
Applying for flare-up (acute) treatment
Flare-up (acute) treatment of FOP with PBS-subsidised palovarotene is Authority Required (Streamlined). You don’t need authority approval from us for the listed quantity and repeats.
More information
Call the PBS Complex Drugs Programs enquiry line for more information.